Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health
This article was originally published in The Tan Sheet
Executive Summary
House Oversight and Government Reform Committee Chairman Henry Waxman is challenging FDA's priorities, saying the agency appears more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health
You may also be interested in...
Chief counsel leaves FDA
Sheldon Bradshaw, chief counsel of FDA, resigned from the agency Sept. 6 to join Hunton & Williams' food and drug law practice, according to the firm. A former Justice Department attorney, Bradshaw served as top lawyer at FDA since 2005, replacing Dan Troy (1"The Tan Sheet" April 11, 2005, p. 7). During his tenure, he reviewed and approved regulations and guidance including a proposed rule clarifying information included in new dietary ingredient notifications and a draft guidance on the kind of scientific data the FDA's Center for Food Safety and Applied Nutrition would find useful in new dietary ingredient submissions. Deputy Chief Counsel Jeffrey Senger will serve as acting chief until a permanent replacement is found, according to FDA staffers in the Office of Chief Counsel...
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.